Nature Search

Role of wild type p53 in the G₂ phase: regulation of the γirradiation-induced delay and DNA repair

Dov Schwartz
Nava Almog
Varda Rotter
Research20 Nov 1997
Oncogene

Volume: 15, P: 2597-2607
G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4

Isabelle Petit
Martine Szyper-Kravitz
Tsvee Lapidot
Research17 Jun 2002
Nature Immunology

Volume: 3, P: 687-694
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Results from the phase IIa COMBAT trial combining CXCR4 and PD-1 inhibition in patients with metastatic cancer show encouraging clinical responses in association with enhanced antitumor immune activation.

Bruno Bockorny
Valerya Semenisty
Manuel Hidalgo
Research25 May 2020
Nature Medicine

Volume: 26, P: 878-885
Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo

A brief, ex vivo incubation of human G-CSF-mobilized peripheral blood grafts with multimerized Fas-Ligand (CD95L), using a closed automated cell processing system, significantly reduces immunoreactivity of the graft in vitro and in vivo.

Galina Rodionov
Michal Rosenzwaig
Amos Ofer
ResearchOpen Access10 May 2022
Bone Marrow Transplantation

Volume: 57, P: 1250-1259
Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance

Hilit Levy-Barazany
Liat Shachnai-Pinkas
Jerry Stein
ResearchOpen Access20 May 2020
Bone Marrow Transplantation

Volume: 55, P: 1305-1316

Quick links

Search

Filter By:

Role of wild type p53 in the G2 phase: regulation of the γirradiation-induced delay and DNA repair

G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo

Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance

Search

Quick links

Role of wild type p53 in the G₂ phase: regulation of the γirradiation-induced delay and DNA repair